Jacek Karas1, Shai Ashkenazi2, Alfredo Guarino3, Andrea Lo Vecchio3, Raanan Shamir4, Yvan Vandenplas5, Hania Szajewska1. 1. Department of Paediatrics, The Medical University of Warsaw, Warsaw, Poland. 2. Schneider Children's Medical Center, Petach-Tikva, Israel Sackler Faculty of Medicine, Felsenstein Medical Research Center, Tel Aviv University, Tel Aviv, Israel. 3. Department of Translational Medical Science, Section of Pediatrics, University of Naples Federico II, Naples, Italy. 4. Institute for Gatroenterology, Nutrition and Liver Diseases, Schneider Children's Medical Center, Petach-Tikva, Israel Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 5. Department of Pediatrics, UZ Brussel, Vrije Universiteit Brussel, Brussels, Belgium.
Abstract
OBJECTIVE: Core outcome sets are the baseline for what should be measured in clinical research and, thus, should serve as a guide for what should be collected and reported. The Consensus Group on Outcome Measures Made in Pediatric Enteral Nutrition Clinical Trials, established in 2012, agreed that consensus on a core set of outcomes with agreed-upon definitions that should be measured and reported in clinical trials was needed. To achieve this goal, six working groups (WGs) were setup, including WG on acute diarrhoea, whose main goal was to develop a core outcome set for trials in acute diarrhoea. METHODS: The first step identified how published outcomes related to acute diarrhoea were reported. The second focused on the methodology for determining which outcomes to measure in clinical trials. The third employed a two-phase questionnaire study using the Delphi technique to define clinically important outcomes to clinicians and parents. RESULTS: For therapeutic studies, the five most important outcome measures were diarrhoea duration, degree of dehydration, need for hospitalisation (or duration of hospitalisation for inpatients), the proportion of patients recovered by 48 h and adverse effects. The prophylactic core outcome set included prevention of diarrhoea, prevention of dehydration, prevention of hospitalisation and adverse effects. CONCLUSIONS: The outcome sets for therapy and prevention can be recommended for use in future trials of patients with gastroenteritis. Their envisioned goal is to decrease study heterogeneity and to ease the comparability of studies. WG's next step is to determine how to measure the outcomes included in the core set. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
OBJECTIVE: Core outcome sets are the baseline for what should be measured in clinical research and, thus, should serve as a guide for what should be collected and reported. The Consensus Group on Outcome Measures Made in Pediatric Enteral Nutrition Clinical Trials, established in 2012, agreed that consensus on a core set of outcomes with agreed-upon definitions that should be measured and reported in clinical trials was needed. To achieve this goal, six working groups (WGs) were setup, including WG on acute diarrhoea, whose main goal was to develop a core outcome set for trials in acute diarrhoea. METHODS: The first step identified how published outcomes related to acute diarrhoea were reported. The second focused on the methodology for determining which outcomes to measure in clinical trials. The third employed a two-phase questionnaire study using the Delphi technique to define clinically important outcomes to clinicians and parents. RESULTS: For therapeutic studies, the five most important outcome measures were diarrhoea duration, degree of dehydration, need for hospitalisation (or duration of hospitalisation for inpatients), the proportion of patients recovered by 48 h and adverse effects. The prophylactic core outcome set included prevention of diarrhoea, prevention of dehydration, prevention of hospitalisation and adverse effects. CONCLUSIONS: The outcome sets for therapy and prevention can be recommended for use in future trials of patients with gastroenteritis. Their envisioned goal is to decrease study heterogeneity and to ease the comparability of studies. WG's next step is to determine how to measure the outcomes included in the core set. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Entities:
Keywords:
Gastroenterology; General Paediatrics; Infectious Diseases; Nutrition
Authors: Bénédicte Sautenet; Allison Tong; Karine E Manera; Jeremy R Chapman; Anthony N Warrens; David Rosenbloom; Germaine Wong; John Gill; Klemens Budde; Lionel Rostaing; Lorna Marson; Michelle A Josephson; Peter P Reese; Timothy L Pruett; Camilla S Hanson; Donal O'Donoghue; Helen Tam-Tham; Jean-Michel Halimi; Jenny I Shen; John Kanellis; John D Scandling; Kirsten Howard; Martin Howell; Nick Cross; Nicole Evangelidis; Philip Masson; Rainer Oberbauer; Samuel Fung; Shilpa Jesudason; Simon Knight; Sreedhar Mandayam; Stephen P McDonald; Steve Chadban; Tasleem Rajan; Jonathan C Craig Journal: Transplantation Date: 2017-08 Impact factor: 4.939
Authors: Paula R Williamson; Douglas G Altman; Heather Bagley; Karen L Barnes; Jane M Blazeby; Sara T Brookes; Mike Clarke; Elizabeth Gargon; Sarah Gorst; Nicola Harman; Jamie J Kirkham; Angus McNair; Cecilia A C Prinsen; Jochen Schmitt; Caroline B Terwee; Bridget Young Journal: Trials Date: 2017-06-20 Impact factor: 2.279
Authors: Nina F Steutel; Marc A Benninga; Miranda W Langendam; Judith J Korterink; Flavia Indrio; Hania Szajewska; Merit M Tabbers Journal: BMJ Open Date: 2017-05-29 Impact factor: 2.692
Authors: Nathan A Pearson; Elizabeth Tutton; Alexander Joeris; Stephen Gwilym; Richard Grant; David J Keene; Kirstie L Haywood Journal: Trials Date: 2021-07-12 Impact factor: 2.279
Authors: Thomas J Lamont; Jan E Clarkson; David N J Ricketts; Peter A Heasman; Craig R Ramsay; Katie Gillies Journal: PLoS One Date: 2021-07-22 Impact factor: 3.240